Loading
Ran the long-term CD19 CAR-T studies in adult leukaemia that showed durable remissions and defined toxicity risk.
Jae H. Park is Director of the Cellular Therapy Service at Memorial Sloan Kettering Cancer Center. He is known for running the long-term CD19 CAR-T studies in adult acute lymphoblastic leukaemia that showed durable remissions and defined toxicity risk, leading MSK's 19-28z CAR-T trials. That work showed that low disease burden at infusion predicts durable remission and lower toxicity. His selected paper reports long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukaemia, and he now directs cellular immunotherapy at MSK.
| Title | Journal | Year |
|---|---|---|
| Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia | New England Journal of Medicine | 2018 |
Shares CD19, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.